EP2215260A4 - Compositions et procédés pour moduler la transduction de signal intracellulaire véhiculé par membrane cellulaire - Google Patents

Compositions et procédés pour moduler la transduction de signal intracellulaire véhiculé par membrane cellulaire

Info

Publication number
EP2215260A4
EP2215260A4 EP08842968A EP08842968A EP2215260A4 EP 2215260 A4 EP2215260 A4 EP 2215260A4 EP 08842968 A EP08842968 A EP 08842968A EP 08842968 A EP08842968 A EP 08842968A EP 2215260 A4 EP2215260 A4 EP 2215260A4
Authority
EP
European Patent Office
Prior art keywords
vehiculated
compositions
methods
signal transduction
intracellular signal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP08842968A
Other languages
German (de)
English (en)
Other versions
EP2215260A1 (fr
Inventor
Richard L Watson
Anthony B Wood
Gregory J Archambeau
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Microdiffusion Inc
Original Assignee
Microdiffusion Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2007/082581 external-priority patent/WO2008115290A2/fr
Priority claimed from PCT/US2007/082578 external-priority patent/WO2008052143A2/fr
Priority claimed from PCT/US2007/082580 external-priority patent/WO2008052145A2/fr
Application filed by Microdiffusion Inc filed Critical Microdiffusion Inc
Publication of EP2215260A1 publication Critical patent/EP2215260A1/fr
Publication of EP2215260A4 publication Critical patent/EP2215260A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N13/00—Treatment of microorganisms or enzymes with electrical or wave energy, e.g. magnetism, sonic waves
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/7036—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin having at least one amino group directly attached to the carbocyclic ring, e.g. streptomycin, gentamycin, amikacin, validamycin, fortimicins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/14—Alkali metal chlorides; Alkaline earth metal chlorides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/08—Antiseborrheics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Obesity (AREA)
  • Inorganic Chemistry (AREA)
EP08842968A 2007-10-25 2008-10-23 Compositions et procédés pour moduler la transduction de signal intracellulaire véhiculé par membrane cellulaire Withdrawn EP2215260A4 (fr)

Applications Claiming Priority (10)

Application Number Priority Date Filing Date Title
US98271907P 2007-10-25 2007-10-25
US98272007P 2007-10-25 2007-10-25
PCT/US2007/082581 WO2008115290A2 (fr) 2006-10-25 2007-10-25 Méthodes de soins et de traitement de plaies
PCT/US2007/082578 WO2008052143A2 (fr) 2006-10-25 2007-10-25 Dispositif de mélange et ses fluides de sortie
PCT/US2007/082580 WO2008052145A2 (fr) 2006-10-25 2007-10-25 Procédés de traitement thérapeutique des yeux et d'autres tissus humains à l'aide d'une solution enrichie en oxygène
US4834008P 2008-04-28 2008-04-28
US4834708P 2008-04-28 2008-04-28
US4833208P 2008-04-28 2008-04-28
US4840408P 2008-04-28 2008-04-28
PCT/US2008/081021 WO2009055614A1 (fr) 2007-10-25 2008-10-23 Compositions et procédés pour moduler la transduction de signal intracellulaire véhiculé par membrane cellulaire

Publications (2)

Publication Number Publication Date
EP2215260A1 EP2215260A1 (fr) 2010-08-11
EP2215260A4 true EP2215260A4 (fr) 2011-04-20

Family

ID=42261767

Family Applications (3)

Application Number Title Priority Date Filing Date
EP08842968A Withdrawn EP2215260A4 (fr) 2007-10-25 2008-10-23 Compositions et procédés pour moduler la transduction de signal intracellulaire véhiculé par membrane cellulaire
EP08841701.9A Active EP2214707B1 (fr) 2007-10-25 2008-10-24 Compositions et procédés pour traiter une inflammation
EP08841991A Withdrawn EP2224924A4 (fr) 2007-10-25 2008-10-24 Compositions et procédés destinés au traitement de la fibrose kystique

Family Applications After (2)

Application Number Title Priority Date Filing Date
EP08841701.9A Active EP2214707B1 (fr) 2007-10-25 2008-10-24 Compositions et procédés pour traiter une inflammation
EP08841991A Withdrawn EP2224924A4 (fr) 2007-10-25 2008-10-24 Compositions et procédés destinés au traitement de la fibrose kystique

Country Status (8)

Country Link
EP (3) EP2215260A4 (fr)
JP (6) JP5613565B2 (fr)
CN (5) CN101910412B (fr)
AU (3) AU2008316794B2 (fr)
CA (3) CA2703672A1 (fr)
IL (3) IL205317A (fr)
MX (3) MX2010004563A (fr)
WO (1) WO2009055614A1 (fr)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6702949B2 (en) 1997-10-24 2004-03-09 Microdiffusion, Inc. Diffuser/emulsifier for aquaculture applications
CA2667791A1 (fr) 2006-10-25 2008-05-02 Revalesio Corporation Procedes de traitement therapeutique des yeux et d'autres tissus humains a l'aide d'une solution enrichie en oxygene
US8445546B2 (en) 2006-10-25 2013-05-21 Revalesio Corporation Electrokinetically-altered fluids comprising charge-stabilized gas-containing nanostructures
JP5306214B2 (ja) 2006-10-25 2013-10-02 リバルシオ コーポレイション 混合装置
US10125359B2 (en) 2007-10-25 2018-11-13 Revalesio Corporation Compositions and methods for treating inflammation
WO2009055620A1 (fr) * 2007-10-25 2009-04-30 Revalesio Corporation Compositions bactériostatiques ou bactériocides et procédés
CA2703672A1 (fr) * 2007-10-25 2009-04-30 Revalesio Corporation Compositions et procedes pour moduler la transduction de signal intracellulaire vehicule par membrane cellulaire
US9523090B2 (en) 2007-10-25 2016-12-20 Revalesio Corporation Compositions and methods for treating inflammation
US9745567B2 (en) 2008-04-28 2017-08-29 Revalesio Corporation Compositions and methods for treating multiple sclerosis
JP5539965B2 (ja) * 2008-04-28 2014-07-02 レバレジオ コーポレイション 多発性硬化症を治療するための組成物および方法
CA2723215A1 (fr) 2008-05-01 2009-11-05 Revalesio Corporation Compositions et methodes de traitement de troubles digestifs
CA2741336A1 (fr) * 2008-10-22 2010-04-29 Revalesio Corporation Compositions et procedes pour le traitement d'affections mediees par la lymphopoietine stromale thymique (tslp)
US8815292B2 (en) 2009-04-27 2014-08-26 Revalesio Corporation Compositions and methods for treating insulin resistance and diabetes mellitus
CA2758738A1 (fr) * 2009-04-27 2010-11-04 Revalesio Corporation Compositions et procedes pour le traitement de la resistance a l'insuline et du diabete
CN104983740A (zh) * 2010-05-07 2015-10-21 利发利希奥公司 用于增强生理性能和恢复时间的组合物和方法
KR20130050952A (ko) 2010-06-16 2013-05-16 브루스 챈들러 메이 인플루엔자, 감기 및 염증의 치료에서 레보세티리진 및 몬테루카스트의 용도
JP2013533320A (ja) 2010-08-12 2013-08-22 レバレジオ コーポレイション タウオパチーを治療するための組成物および方法
AU2011289176B2 (en) * 2010-08-13 2015-09-24 Revalesio Corporation Compositions and methods for treating cardiovascular disease
CN103561722A (zh) * 2011-04-13 2014-02-05 利发利希奥公司 用于抑制和／或调整炎性神经变性疾病中涉及到的效应t细胞的组合物和方法
JP6368459B2 (ja) * 2012-06-14 2018-08-01 松本　高明 点眼液の製造方法
ES2654093T3 (es) 2013-03-13 2018-02-12 Inflammatory Response Research, Inc. Uso de levocetirizina y montelukast en el tratamiento de trastornos autoinmunes
CA2901413A1 (fr) 2013-03-13 2014-10-09 Bruce Chandler May Utilisation de levocetirizine et de montelukast dans le traitement de la vascularite
RU2672871C2 (ru) 2013-03-13 2018-11-20 Инфламматори Респонс Ресёрч, Инк. Применение левоцетиризина и монтелукаста при лечении травматических повреждений
JP2017526728A (ja) 2014-09-15 2017-09-14 インフラマトリー・レスポンス・リサーチ・インコーポレイテッド 炎症介在性状態の治療におけるレボセチリジン及びモンテルカスト
CN106943593A (zh) * 2017-03-24 2017-07-14 浙江中医药大学 抗tslp抗体在制备防治慢性瘙痒药物中的应用
KR20200035235A (ko) * 2017-05-23 2020-04-02 바이오바이트 오스트레일리아 피티와이 엘티디 아르트로스피라로부터의 추출물들 및 그 용도들
EP4153178A4 (fr) 2020-05-19 2024-06-05 Irr, Inc. Lévocétirizine et montélukast utilisés dans le traitement du sepsis et de ses symptômes
CN112305153B (zh) * 2020-10-16 2022-09-23 中石化石油工程技术服务有限公司 一种膨润土含量的自动分析检测仪及其检测方法

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6386751B1 (en) * 1997-10-24 2002-05-14 Diffusion Dynamics, Inc. Diffuser/emulsifier
DE10227818A1 (de) * 2002-06-21 2004-01-08 Pakdaman, Abolghassem, Prof. Dr.med. Gasanreicherungsmodule
WO2004022098A1 (fr) * 2002-09-09 2004-03-18 Borsos Ferenc Eau enrichie en oxygene, traitee dans un champ magnetique et eau lourde
US20050047270A1 (en) * 1997-10-24 2005-03-03 Wood Anthony B. System and method for therapeutic application of dissolved oxygen
WO2005113026A2 (fr) * 2004-04-22 2005-12-01 Medical Discoveries, Inc. Procede de traitement des troubles respiratoires et de l'inflammation des voies respiratoires
US20060216360A1 (en) * 2005-03-28 2006-09-28 Dabur Pharma Ltd. Stable pharmaceutical compositions of platinum (II) antitumour agents
WO2008052143A2 (fr) * 2006-10-25 2008-05-02 Revalesio Corporation Dispositif de mélange et ses fluides de sortie

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9518483D0 (en) * 1995-09-09 1995-11-08 Thompson Royce Ltd Lighting control systems
DK1100811T3 (da) * 1998-07-28 2007-11-05 Univ California Nucleinsyrer, som koder for en G-protein-koblet receptor involveret i sensorisk transduktion
US20060198901A9 (en) * 1999-10-26 2006-09-07 Holloway William D Jr Drugs, bio-affecting and body treating compositions
NZ518605A (en) * 1999-10-26 2004-03-26 Bio Hydration Res Lab Inc Micro-cluster liquids and methods of making and using them
JP2003516150A (ja) * 1999-12-08 2003-05-13 ジェンセット 潜在性分泌タンパク質をコードする全長ヒトｃＤＮＡ
US7255881B2 (en) * 2000-07-27 2007-08-14 Nucryst Pharmaceuticals Corp. Metal-containing materials
AU2001292867A1 (en) * 2000-09-20 2002-04-02 The Cleveland Clinic Foundation Ligands for g protein coupled receptors and methods of using them
US20040235732A1 (en) * 2000-11-03 2004-11-25 Qun-Yong Zhou Method for modulating angiogenesis using prokineticin receptor antagonists
JP2004529090A (ja) * 2001-02-01 2004-09-24 ハイドロン テクノロジーズ，インク． 組織に酸素を供給する超酸素化組成物及び方法
GB0118383D0 (en) * 2001-07-27 2001-09-19 Pharmagene Lab Ltd Therapeutic methods
US7790762B2 (en) * 2002-10-31 2010-09-07 National Jewish Health Compounds and methods for thiol-containing compound efflux and cancer treatment
US7491695B2 (en) * 2003-06-18 2009-02-17 Tranzyme Pharma Inc. Methods of using macrocyclic modulators of the ghrelin receptor
CN1922156A (zh) * 2003-11-10 2007-02-28 默克公司 作为钠通道阻断剂的取代的三唑
US20050139808A1 (en) * 2003-12-30 2005-06-30 Oculus Innovative Sciences, Inc. Oxidative reductive potential water solution and process for producing same
EP2594272B1 (fr) * 2005-05-18 2018-07-11 Horizon Orphan LLC Fluoroquinolones en aérosol et leurs utilisations
GB0603683D0 (en) * 2006-02-23 2006-04-05 Novartis Ag Organic compounds
CA2667791A1 (fr) * 2006-10-25 2008-05-02 Revalesio Corporation Procedes de traitement therapeutique des yeux et d'autres tissus humains a l'aide d'une solution enrichie en oxygene
EP2083876A4 (fr) * 2006-10-25 2012-09-19 Revalesio Corp Méthodes de soins et de traitement de plaies
WO2009055620A1 (fr) * 2007-10-25 2009-04-30 Revalesio Corporation Compositions bactériostatiques ou bactériocides et procédés
CA2703672A1 (fr) * 2007-10-25 2009-04-30 Revalesio Corporation Compositions et procedes pour moduler la transduction de signal intracellulaire vehicule par membrane cellulaire

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6386751B1 (en) * 1997-10-24 2002-05-14 Diffusion Dynamics, Inc. Diffuser/emulsifier
US20050047270A1 (en) * 1997-10-24 2005-03-03 Wood Anthony B. System and method for therapeutic application of dissolved oxygen
DE10227818A1 (de) * 2002-06-21 2004-01-08 Pakdaman, Abolghassem, Prof. Dr.med. Gasanreicherungsmodule
WO2004022098A1 (fr) * 2002-09-09 2004-03-18 Borsos Ferenc Eau enrichie en oxygene, traitee dans un champ magnetique et eau lourde
WO2005113026A2 (fr) * 2004-04-22 2005-12-01 Medical Discoveries, Inc. Procede de traitement des troubles respiratoires et de l'inflammation des voies respiratoires
US20060216360A1 (en) * 2005-03-28 2006-09-28 Dabur Pharma Ltd. Stable pharmaceutical compositions of platinum (II) antitumour agents
WO2008052143A2 (fr) * 2006-10-25 2008-05-02 Revalesio Corporation Dispositif de mélange et ses fluides de sortie

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO2009055614A1 *

Also Published As

Publication number Publication date
AU2008316623A1 (en) 2009-04-30
JP2014169328A (ja) 2014-09-18
IL205317A0 (en) 2010-12-30
CN101910412A (zh) 2010-12-08
IL205318A (en) 2017-01-31
EP2224924A4 (fr) 2011-01-12
MX2010004563A (es) 2010-07-28
CN103933567A (zh) 2014-07-23
JP2011500837A (ja) 2011-01-06
JP5869763B2 (ja) 2016-02-24
EP2214707A4 (fr) 2011-04-20
CN101910412B (zh) 2013-08-21
MX2010004564A (es) 2010-07-28
CN101909648B (zh) 2014-04-16
IL205318A0 (en) 2010-12-30
MX2010004554A (es) 2010-07-28
WO2009055614A1 (fr) 2009-04-30
CA2703672A1 (fr) 2009-04-30
CA2703754C (fr) 2019-04-09
CA2703739A1 (fr) 2009-04-30
EP2214707B1 (fr) 2017-07-12
IL205319A0 (en) 2010-12-30
AU2008316794B2 (en) 2015-04-23
JP2014193915A (ja) 2014-10-09
EP2224924A1 (fr) 2010-09-08
CA2703754A1 (fr) 2009-04-30
CN101909623A (zh) 2010-12-08
CN101909623B (zh) 2015-04-01
JP2014205693A (ja) 2014-10-30
JP5613565B2 (ja) 2014-10-22
AU2008316663A1 (en) 2009-04-30
JP2011500844A (ja) 2011-01-06
AU2008316794A1 (en) 2009-04-30
CN101909648A (zh) 2010-12-08
IL205317A (en) 2016-03-31
IL205319A (en) 2016-06-30
JP2011500847A (ja) 2011-01-06
AU2008316663B2 (en) 2014-12-18
AU2008316623B2 (en) 2015-01-22
EP2214707A1 (fr) 2010-08-11
JP5911197B2 (ja) 2016-04-27
CN104771758A (zh) 2015-07-15
EP2215260A1 (fr) 2010-08-11

Similar Documents

Publication Publication Date Title
EP2215260A4 (fr) Compositions et procédés pour moduler la transduction de signal intracellulaire véhiculé par membrane cellulaire
WO2008008857A3 (fr) Macromolécules thiolées et procédés de fabrication et d'utilisation de celles-ci
EP2215126A4 (fr) Compositions et procédés de modulation du recollage de membranes cellulaires
DK1839071T3 (da) Marineradarapparat
EP2187965A4 (fr) Conjugués ligand-lieur de liaison au psma et procédés pour utiliser ceux-ci
EP2046391A4 (fr) Vecteurs de médicament, leur synthèse, et procédés pour leur utilisation
CR10717A (es) Compositions and methods for modulating c-kit and pdgfr receptors
AP2008004633A0 (en) Method for the synthesis of 5-alkoxymethyl furfural ethers and their use
EP2331558A4 (fr) Monomères protégés et procédés de déprotection pour la synthèse de l arn
HUE056772T2 (hu) Biaxálisan orientált mikroporózus membrán
GB201020953D0 (en) Nanopore membrane
EP2046996A4 (fr) Procédés pour la sélection des médicaments
EP1980089A4 (fr) Évaluation non intrusive de la qualité d'un signal
NO20045647D0 (no) Akustiske transdusere for rorledninger
EP2134171A4 (fr) Compositions et procédés pour la formation et le remodelage osseux
EP2219491A4 (fr) Sangles de serrage et procédés pour les fabriquer, les vendre et les utiliser
EP2012806A4 (fr) Procédés et compositions permettant de modifier la fonction cellulaire
WO2008058127A3 (fr) Anticorps d'agonistes de trkb et leurs utilisations
EP1894330A4 (fr) Transducteur selectif pour communications
DK1912476T3 (da) Fremgangsmåde til træning af høreevne
EP2265274A4 (fr) Adjuvants pour réduire la toxicité du méthotrexate, et procédés d utilisation
EP2068904A4 (fr) Procédés pour préparer des diazonamides
EP1817423A4 (fr) Melangeurs pour chimiolyse de cellules
EP1873502A4 (fr) Balance combinée pour le pesage de mélanges
EP2366024A4 (fr) Compositions, procédés et utilisations pour induire la croissance virale

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20100521

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MT NL NO PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL BA MK RS

DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20110321

RIC1 Information provided on ipc code assigned before grant

Ipc: C12N 5/00 20060101ALI20110315BHEP

Ipc: A61K 33/00 20060101ALI20110315BHEP

Ipc: C12Q 1/68 20060101AFI20090520BHEP

17Q First examination report despatched

Effective date: 20120326

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20170503